Bayer speeds up spinoff of plastics unit; Parexel chops 850 jobs amid corporate reshuffling;

@FiercePharma: HIV vaccine research a 'major advance,' NIH official says. FierceVaccines story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> Bayer looks to be accelerating the spinoff of its plastics unit, planning to finish preparations for the deal by late August, sources familiar with the matter told Reuters. Story

> CRO Parexel is laying off 850 employees amid a corporate overhaul, eyeing savings of between $50 million and $60 million once the reshuffling is complete. More

> European regulators gave their thumbs-up to Daiichi Sankyo's once-daily bloodthinner Lixiana to treat and prevent strokes in adult patients. Article

> The FDA is planning to hold a public panel meeting to hash out safety concerns for Bayer's contraceptive device, Essure. Story

> Novo Nordisk ($NVO) revealed data from two studies showing the emotional and physical toll hemophilia takes on patients and caregivers of people with the disorder. More

> The FDA issued a warning against Noven Therapeutics' Daytrana patch for ADHD, saying the drug may cause permanent loss of skin color, or chemical leukoderma. Statement

Medical Device News

@FierceMedDev: Google and the Broad Institute join forces for genomic data sharing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Chris Viehbacher explains: "If I had $2 billion to invest…" More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Enthusiasm could be outpacing the evidence when it comes to genetic testing, experts say. More from the NYT | Follow @EmilyWFierce

> Zimmer Biomet is born after knee implant divestiture to S&N. More

> FDA panel slated to weigh Bayer Essure safety after more than 5,000 complaints. Story

> Covidien settles the score in more than 11,000 vaginal mesh cases. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Little NeuroRx boasts big about a new ketamine combo for bipolar depression. Article | Follow @FierceBiotech

@JohnCFierce: Isn't it strange that biotech is booming and R&D jobs have never been so uncertain? | Follow @JohnCFierce

> Catabasis pulls off a $60M IPO as biotech's Wall Street window stays open. Article

> London's mayor suggests quick $15B fix for financially ailing biotech sector. Story

> Bristol-Myers rips up its R&D group, adding, eliminating and moving hundreds. Report

Vaccines News

> Vical posts herpes vaccine PhI/II failure, gutting shares. News

> MERS getting more attention as vaccine candidate enters PhI. More

> ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines. Story

> NIH grants Northeastern prof $1.4M to address 'bottleneck' in vaccine development. Article

> Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M. Report

CRO News

> PRA debuts a sweeping clinical trial operating system. More

> Novasep bets $11M on armed antibody R&D. Item

> Huntingdon and Harlan move forward under a new monicker. Article

> Icon rolls out some new patient-consent tech with a focus on education. Story

> Parexel cutting 850 jobs as it dims its revenue outlook. Report

Pharma Asia News

> S. Korea sees extra $9B in spending to handle MERS outbreak. Report

> Australia's Benitec heading for Nasdaq IPO. More

> Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies. Story

> CRO M&A ticks up in India, fueling hopes of turnaround. Article

> South Korea biopharma IPOs highlight demand. Item

Pharma Manufacturing News

> Novasep building ADC manufacturing plant at Le Mans site. News

> Pharmacies want more time to comply with track-and-trace rules. Item

> TxCell halts drug production, a decision made with French regulator. Report

> FDA slaps U.S. drugmaker over drug testing issues. Story

> Hospira finally up and running at its cost-cutting India plant. Article

And Finally… Pfizer's ($PFE) arthritis drug Xeljanz restored skin color in a patient with the disfiguring skin condition vitiligo, according to dermatologists at Yale School of Medicine. Story

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.